Incyte stock
Price history
+15.54% over the period1 year: from $104.17 (November 17, 2025) to $120.36 (November 17, 2026), +15.54%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $120.36 |
| October 30, 2026 | $120.39 |
| September 30, 2026 | $121.35 |
| August 31, 2026 | $123.22 |
| July 31, 2026 | $119.52 |
| June 30, 2026 | $113.36 |
| May 29, 2026 | $96.74 |
| April 30, 2026 | $95.27 |
| March 31, 2026 | $94.12 |
| February 27, 2026 | $101.27 |
| January 30, 2026 | $100.07 |
| December 31, 2025 | $98.77 |
| November 28, 2025 | $104.46 |
| November 17, 2025 | $104.17 |
At a glance
The company
Discovers, develops and commercializes biopharmaceutical therapeutics in the United States, Europe, Canada and Japan
Latest results
Quarter to September 30, 2026 · EPS -$3.60 (estimate -$3.53)
TickerLandia's take on Incyte
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 19 vs a median of 43 over its last 7 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 61 vs 33 (+86%) in a group of 6.
- Strong point: Financial strength (83/100 in its group). Weak point: Growth (37/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−10.19% from the 52-week high
Analysts · 28 analysts
Average target$132.25+11.05% vs. price
Buy 13 · Hold 14 · Sell 1 · Buy
TickerLandia Fingerprint: Incyte
Compared with similar companies: very high financial strength.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricelow31
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 61.0 73 EV/EBITDA 10.2 14 Price/book 4.32 30 Price/sales 4.05 18 Forward P/E 13.9 19 Profitabilityaverage59
How much it earns on revenue and capital.
Metric Value Position in group ROE 7.8% 43 ROA 17.8% 93 Gross margin 56.0% 34 Operating margin 32.2% 80 Net margin 6.7% 45 Earnings stabilityhigh78
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 10.1% 73 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthlow37
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +14.84% 38 Revenue growth (year over year) +14.00% 37 Financial strengthvery high83
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −2.11 88 Current ratio 3.84 61 Interest coverage 554.6 95 Debt/equitycounts in reverse: lower means more financial strength 0.01 89 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong65
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +0.70% 50 Relative strength (6 months) +24.81% 84 1-year return +14.32% 53 Distance from 200-day average +9.16% 71 Risklow32
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 18.3% 20 Volatility (60 days) 29.0% 35 Beta (1 year) 0.48 40
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Incyte is cheaper than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Incyte's P/E today is 18.8, below the median of its last 7 fiscal years (42.6; between 15.4 and 185.7 from 2016 to 2025). Incyte's P/E (trailing 12 months): 61.0, +86% against the median of a group of 6 similar companies (32.7).
Compared with 6 similar companies
| Metric | Incyte | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 61.0 | High | |
| Forward P/E | 13.9 | Middle | |
| Operating margin | 32.2% | High | |
| ROE | 7.8% | Middle | |
| Debt/equity | 0.01 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Incyte. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$1.56B
Latest quarter · Q3 2026
Net income
-$784.8M
Latest quarter · Q3 2026
Quarterly net margin
-50.4%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $24.36B
- P/E
- 61.0
- EPS
- $1.96
- Volume
- 858.15K
- Daily trading
- €195.71M
- Dividend yield
- 0.00%
How Incyte is changing
All resultsRevenue grew 14.0% a year on average over the last 5 years
Operating margin rose from 17.1% to 29.5%
Profits turn into cash: free cash flow equal to 108% of net income
Returns
Incyte returns
$1,000 invested in Incyte 5 years ago, on November 17, 2021, would be worth $1,851 today: +85.11% in total, +13.11% per year. This is the price return only: dividends are excluded.
| Period | Incyte | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +6.28% | −3.17% | $1,063 |
| 6 months | +24.95% | +0.11% | $1,250 |
| Year to date | +21.86% | +8.34% | $1,219 |
| 1 year | +15.54% | +11.15% | $1,155 |
| 3 years | +121.78% | +64.30% | $2,218 |
| 5 years | +85.11% | +58.18% | $1,851 |
| 10 years | +14.03% | +239.10% | $1,140 |
Over the last 6 months it has done better than 64% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Incyte: technical analysis
Incyte is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 22.0% below its all-time closing high ($152.66, March 15, 2017).
- Trend
- Upward
- RSI (14 sessions)
- 50
- Between 30 and 70
- vs 200-session average
- +9.16%
Support and resistance
Price areas where Incyte has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$129.84+9.03%3 touches, last on September 18, 2026
- Resistance$119.51+0.36%3 touches, last on September 15, 2026
- Last price$119.09
- Support$115.38−3.11%2 touches, last on November 6, 2026
- Support$111.05−6.75%4 touches, last on October 29, 2026
- Support$108.36−9.01%4 touches, last on October 13, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.48
- Volatility (60 sessions, annualised)
- 29.0%
- Largest fall in the last year
- −18.33%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Incyte: seasonality
Average monthly price change over 33 years
Over the last 33 years, the strongest month for Incyte has been December: +9.13% on average, positive in 19 years out of 33. The weakest has been March: −3.98% on average, positive in 14 years out of 33. November, the current month, has been positive in 19 years out of 32 (+6.09% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +8.42% | +7.37% | 21 of 33 |
| February | −0.15% | −3.14% | 11 of 33 |
| March | −3.98% | −1.89% | 14 of 33 |
| April | −1.04% | −0.28% | 16 of 33 |
| May | +6.02% | +2.04% | 20 of 33 |
| June | +2.87% | +1.19% | 20 of 33 |
| July | +1.71% | +0.71% | 18 of 33 |
| August | +1.95% | +1.27% | 18 of 33 |
| September | −1.33% | −5.38% | 13 of 33 |
| October | +2.01% | +2.23% | 17 of 33 |
| November | +6.09% | +1.78% | 19 of 32 |
| December | +9.13% | +2.89% | 19 of 33 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Incyte and its competitors
JAKAFI, ICLUSIG, MONJUVI, NIKTIMVO, PEMAZYRE and ZYNYZ are the Incyte Corporation medicines most widely known, and the company discovers, develops and commercializes therapeutics. Its marketed products treat myelofibrosis, polycythemia vera, chronic myeloid leukemia, diffuse large B-cell lymphoma and Merkel cell carcinoma, while clinical-stage candidates target ovarian cancer, atopic dermatitis, hidradenitis suppurativa and vitiligo. Products are sold to specialty and retail pharmacies, hospital pharmacies and distributors in the United States, Europe, Canada and Japan.
- Headquarters
- Wilmington, United States
- Employees
- 2,844
- Founded
- 1991
- Chief executive
- William Meury
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| IncyteINCY | $24.36B | 32.2% | 61.0 | +24.95% |
| Alnylam PharmaceuticalsALNY | $22.11B | 19.5% | 8.34 | −45.47% |
| InsmedINSM | $26.96B | -41.7% | — | +11.65% |
| BioNTechBNTX | $21.22B | -55.4% | — | −5.24% |
| Roivant SciencesROIV | $28.64B | -3,226.3% | — | +32.16% |
| Ascendis PharmaASND | $18.06B | 30.9% | 18.1 | +12.76% |
Same industry or related industries, similar size. Compare Incyte with its competitors · Full profile
